Omega-3 phospholipid fails to improve triglyceride levels in phase III trial

In the TRILOGY 2 trial CaPre (omega-3 phospholipid) failed to provide a statistically significant reduction in triglyceride levels vs placebo. Manufacturers state that they intend to perform post-hoc explorations.

Biospace Inc.